Novavax, Inc. (NASDAQ:NVAX) Receives Average Recommendation of “Buy” from Brokerages


Share on StockTwits

Shares of Novavax, Inc. (NASDAQ:NVAX) have earned an average rating of “Buy” from the eight brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $217.69.

A number of research firms have weighed in on NVAX. HC Wainwright increased their price target on shares of Novavax from $207.00 to $317.00 and gave the stock a “buy” rating in a research note on Thursday, March 18th. B. Riley increased their price target on shares of Novavax from $223.00 to $334.00 and gave the stock a “buy” rating in a research note on Monday, February 1st. Cantor Fitzgerald raised their target price on shares of Novavax from $248.00 to $338.00 and gave the company an “overweight” rating in a research note on Friday, February 5th. Finally, Zacks Investment Research raised shares of Novavax from a “sell” rating to a “strong-buy” rating and set a $134.00 target price on the stock in a research note on Tuesday, January 12th.

NASDAQ NVAX traded up $6.68 during mid-day trading on Friday, reaching $201.34. 4,971,509 shares of the stock were exchanged, compared to its average volume of 4,229,188. Novavax has a 1-year low of $16.41 and a 1-year high of $331.68. The business’s fifty day simple moving average is $196.83 and its 200 day simple moving average is $153.02. The stock has a market capitalization of $14.87 billion, a PE ratio of -38.57 and a beta of 2.01. The company has a debt-to-equity ratio of 3.61, a quick ratio of 2.81 and a current ratio of 2.81.

Novavax (NASDAQ:NVAX) last announced its earnings results on Monday, March 1st. The biopharmaceutical company reported ($2.70) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.53) by ($1.17). Novavax had a negative return on equity of 1,346.17% and a negative net margin of 133.10%. The firm had revenue of $279.66 million for the quarter, compared to analyst estimates of $202.44 million. During the same quarter last year, the business posted ($1.13) EPS. The firm’s revenue was up 3072.2% compared to the same quarter last year. On average, analysts anticipate that Novavax will post -5.49 EPS for the current year.

In related news, Director Michael A. Mcmanus, Jr. sold 4,000 shares of the firm’s stock in a transaction on Friday, March 19th. The shares were sold at an average price of $220.78, for a total transaction of $883,120.00. Following the completion of the sale, the director now directly owns 8,951 shares of the company’s stock, valued at approximately $1,976,201.78. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Gregory M. Glenn sold 2,434 shares of the firm’s stock in a transaction on Thursday, February 18th. The shares were sold at an average price of $269.57, for a total transaction of $656,133.38. Over the last ninety days, insiders have sold 64,497 shares of company stock valued at $13,928,932. Company insiders own 3.30% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. IFP Advisors Inc grew its holdings in Novavax by 39.4% during the 4th quarter. IFP Advisors Inc now owns 336 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 95 shares in the last quarter. Arkadios Wealth Advisors grew its holdings in Novavax by 20.0% during the 4th quarter. Arkadios Wealth Advisors now owns 600 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 100 shares in the last quarter. Bedel Financial Consulting Inc. grew its holdings in Novavax by 46.4% during the 4th quarter. Bedel Financial Consulting Inc. now owns 366 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 116 shares in the last quarter. Oppenheimer & Co. Inc. grew its holdings in Novavax by 3.5% during the 4th quarter. Oppenheimer & Co. Inc. now owns 3,997 shares of the biopharmaceutical company’s stock worth $446,000 after acquiring an additional 137 shares in the last quarter. Finally, Cetera Advisors LLC grew its holdings in Novavax by 1.7% during the 4th quarter. Cetera Advisors LLC now owns 8,251 shares of the biopharmaceutical company’s stock worth $920,000 after acquiring an additional 141 shares in the last quarter. 49.91% of the stock is owned by institutional investors.

Novavax Company Profile

Novavax, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.

Recommended Story: The basics of gap trading strategies

Analyst Recommendations for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.